Newswire (Published: Monday, February 20, 2017, Received: Thursday, February 16, 2017, 3:54:32 PM CST)

Word Count: 430

Researchers at Huashan Hospital Have Reported New Data on Prostate Cancer (An Open-Label Pilot Study of Metformin as a Concomitant Therapy on Patients with Prostate Cancer Undergoing Androgen Deprivation Treatment)

By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting out of Shanghai, People's Republic of China, by NewsRx editors, research stated, "The study aimed to evaluate the effects of metformin on insulin, C-peptide and body weight in Chinese men undergoing androgen deprivation therapy (ADT). Between March 2013 and June 2014, 62 newly diagnosed patients of prostate cancer (PCa) due to receive ADT were recruited from 7 hospitals in Shanghai."

Our news journalists obtained a quote from the research from Huashan Hospital, "Patients were randomized to respectively receive ADT (n=31) and ADT + metformin (n=31) for 6 months. Fasting and postprandial serum levels of insulin and C-peptide, blood glucose, prostate specific antigen, body mass index (BMI) and waist circumference (WC) were measured at the beginning and end of 6-month treatment. Baseline characteristics were comparable between the 2 groups. Controlling for baseline levels, the ADT group had significantly higher levels of fasting glucose (p=0.01) and higher WC (p=0.04) than the ADT + metformin group. The levels of insulin, C-peptide and BMI did not differ significantly."

According to the news editors, the research concluded: "Metformin may be potentially efficient as a concomitant therapy on patients with PCa undergoing androgen deprivation treatment."

For more information on this research see: An Open-Label Pilot Study of Metformin as a Concomitant Therapy on Patients with Prostate Cancer Undergoing Androgen Deprivation Treatment. Urologia Internationalis, 2016;98(1):79-84. (Karger -; Urologia Internationalis -

Our news journalists report that additional information may be obtained by contacting W. Zhu, Dept. of and Institute of Urology, Huashan Hospital, Shanghai, People's Republic of China. Additional authors for this research include H. Xu, J. Ma, J. Guo, W. Xue, B. Gu, L. Sheng, X. Yao, F. Sun, J. Gong, W. Qiu, Q. Ding and H. Jiang (see also Oncology - Prostate Cancer).

Keywords for this news article include: Asia, Antidiabetic Agents, Shanghai, Oncology, Androgens, C Peptide, Biguanides, Proinsulin, Prostate Cancer, Peptide Hormones, Peptide Proteins, Clinical Research, Metformin Therapy, Non Sulfonylureas, Drugs and Therapies, Hypoglycemic Agents, Prostatic Neoplasms, People's Republic of China, Clinical Trials and Studies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC


      Healthcare Facilities


Eastern Asia
People's Republic of China


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Health Sciences
            Medical Research
      Medical Specialties and Practices
      Treatments and Therapies
            Medicinal Drugs